Ensysce Biosciences (ENSCW) Gains from Investment Securities (2018 - 2025)
Ensysce Biosciences (ENSCW) reported Gains from Investment Securities of $102785.0 for Q4 2025, up 165.01% year-over-year from $38785.0 in Q4 2024, and little changed quarter-over-quarter from $102785.0 in Q3 2025.
Ensysce Biosciences (ENSCW) Gains from Investment Securities (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 8 years of Gains from Investment Securities data on file, last reported at $102785.0 in Q4 2025.
- Gains from Investment Securities for Q4 2025 came in at $102785.0, up 165.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $102785.0 (up 165.01% YoY), and the FY2025 annual result was $102785.0, up 165.01% from the prior year.
- Gains from Investment Securities held at $102785.0 in Q4 2025 per ENSCW's latest filing, from $102785.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $4.4 million in Q2 2021 and troughed at $1600.0 in Q1 2021.
- A 5-year average of $620997.3 and a median of $45392.5 in 2023 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities tumbled 99.79% in 2022, then jumped 2109.14% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $4.4 million in 2021, then plunged by 99.79% to $9545.0 in 2022, then soared by 306.34% to $38785.0 in 2023, then changed by 0.0% to $38785.0 in 2024, then surged by 165.01% to $102785.0 in 2025.
- Business Quant data shows ENSCW's Gains from Investment Securities at $102785.0 in Q4 2025, $102785.0 in Q3 2025, and $102785.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ensysce Biosciences | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 102,785.00 |
| Dec 31, 2025 | 102,785.00 |
| Sep 30, 2025 | 102,785.00 |
| Sep 30, 2025 | 102,785.00 |
| Jun 30, 2025 | 102,785.00 |
| Jun 30, 2025 | 102,785.00 |
| Mar 31, 2025 | 52,000.00 |
| Mar 31, 2025 | 52,000.00 |
| Dec 31, 2024 | 38,785.00 |
| Dec 31, 2024 | 38,785.00 |
| Sep 30, 2024 | 581,314.00 |
| Sep 30, 2024 | 581,314.00 |
| Jun 30, 2024 | 581,314.00 |
| Jun 30, 2024 | 581,314.00 |
| Mar 31, 2024 | 581,315.00 |
| Mar 31, 2024 | 581,315.00 |
| Dec 31, 2023 | 38,785.00 |
| Dec 31, 2023 | 38,785.00 |
| Sep 30, 2023 | 26,314.00 |
| Sep 30, 2023 | 26,314.00 |